If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
224
results.
Updated on
15/10/2025 [07:00:00]
Results 150 to 175 of 224
Absstract of: US2025302971A1
Disclosed herein is a delivery vehicle based on DNA-inspired Janus based nanotubes (JBNTs) for anti-viral treatment. The nanoparticles (NPs) are based the JBNTs conjugated with targeting moieties such as small molecules, aptamers, and peptides.
Absstract of: US2025304547A1
Provided herein are novel sulfur-containing lipids having a structure of Formula A or a salt thereof. The compounds may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acids for use in the targeting of a non-liver organ, tissue or cell. Further provided are methods for making the compounds. (Formula A)
Absstract of: US2025302765A1
The triacetyl andrographolide nanocrystal is mainly composed of triacetyl andrographolide, a stabilizer and an excipient, and an average particle size of drug particles in a triacetyl andrographolide nanocrystal suspension obtained by redissolving the triacetyl andrographolide nanocrystal in water, is less than 500 nm, and a PDI is less than 0.2. The nanocrystal suspension is prepared from the triacetyl andrographolide and the stabilizer by a high-speed shear anti-solvent method in combination with a high-pressure homogenization method, then the excipient is added, and the nanocrystal is prepared through spray-drying.
Absstract of: US2025302769A1
Compositions and methods of making and using silver nanoparticles embedded in biomass waste matrixes of various types is described. Exemplified compositions include a silver nanoparticle embedded in a cotton gin waste nanofiber composite. Compositions and methods of making and using aerogels comprising silver nanoparticles in cotton gin waste nanofiber are described. Exemplified uses of compositions include use as antimicrobial agents.
Absstract of: US2025302762A1
A self-assembled nanomaterial includes a Janus base nanotube, wherein the Janus base nanotube includes at least one compound represented by Formulas I to XII, or a pharmaceutically acceptable salt thereof. Also described are compositions including the Janus base nanotubes.
Absstract of: US2025302824A1
The present disclosure relates to an in situ ready-to-use injection formulation of posaconazole free of cyclodextrin and derivatives of cyclodextrin, which can be formulated in situ as a nanosuspension injection of posaconazole by a simple dilution operation during clinical use. The formulation has no adverse effects on the renal function of patients, no extreme pH, and low vascular irritation, and can be administrated without the need for central venous cannulation during clinical use. The present disclosure also relates to a method for preparing the formulation and the use of the formulation in the treatment and prevention of fungal infections.
Absstract of: US2025302747A1
Disclosed herein are novel lipids, lipid nanoparticlcs and their uses for the transport of therapeutic agents to a subject, or for the treatment and/or prophylaxis of diseases in the subject.
Absstract of: US2025302991A1
Provided are a novel lipid derivative compound including oligo-γ-glutamic acid, a lipid nanoparticle composition including the same, and the like. According to the present disclosure, the compound may form lipid nanoparticles by replacing PEGylated lipid, thereby preventing side effects such as anaphylaxis and exhibiting excellent in vivo stability, making it useful as a novel drug delivery system.
Absstract of: US2025302989A1
A chitosan-heparin nanomotor and a method for producing same are disclosed. A STING agonist-encapsulated urease-based chitosan-heparin nanomotor delivers the STING agonist directly to bladder mucosal cells in the bladder, and thus can induce an immune response.
Absstract of: AU2024254671A1
The invention relates to a method for producing a lipid-based nanoparticle comprising an antigen binding domain and one or several nucleic acid molecule(s) using a mixing device, to a lipid-based nanoparticle comprising an antigen-binding domain and one or several nucleic acid molecule(s) obtainable trough such method and to uses thereof.
Absstract of: AU2025201939A1
The present invention relates to engineered targeted lipid nanoparticles (LNPs) comprising a nucleic acid, and compositions thereof, wherein the LNPs or compositions are capable of traversing the blood brain barrier (BBB) and delivering nucleic acid cargoes to a target tissue or cell in the central nervous system. In one aspect, the invention relates to the treatment of a neurological disease or disorder with a LNP or composition of the invention. The present invention relates to engineered targeted lipid nanoparticles (LNPs) comprising a nucleic acid, and compositions thereof, wherein the LNPs or compositions are capable of traversing the blood brain barrier (BBB) and delivering nucleic acid cargoes to a target tissue or cell in the central nervous system. In one aspect, the invention relates to the treatment of a neurological disease or disorder with a LNP or composition of the invention. ar a r h e p r e s e n t i n v e n t i o n r e l a t e s t o e n g i n e e r e d t a r g e t e d l i p i d n a n o p a r t i c l e s ( s ) c o m p r i s i n g a n u c l e i c a c i d , a n d c o m p o s i t i o n s t h e r e o f , w h e r e i n t h e s o r c o m p o s i t i o n s a r e c a p a b l e o f t r a v e r s i n g t h e b l o o d b r a i n b a r r i e r ( ) a n d d e l i v e r i n g n u c l e i c a c i d c a r g o e s t o a t a r g e t t i s s u e o r c e l l i n t h e c e n t r a l n e r v o u s s y s t e m n o n e a s p e c t , t h e i n v e n t i o n r e l a t e s t o t h e t r
Absstract of: AU2024250699A1
The present disclosure provides novel compounds, methods, and cell targeting mRNA vaccine formulations for targeted delivery, such as delivery to dendritic cells. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features specific for dendritic cells and a lipid tail for incorporated into the bilayer membrane of the formed lipid nanoparticle.
Absstract of: AU2024249750A1
Peptides which are capable of penetrating mucosal membranes or cell membranes are provided. In some aspects, functionalized peptide conjugates are provided. Compositions of peptide conjugates are disclosed, and methods of using such compositions are provided.
Absstract of: AU2024229078A1
The present invention relates to nanocomplexes (NCs) comprising a polysaccharide nanoparticle (NP) and a hormone selected from insulin, glucagon, or glucagon-like protein-1, and uses thereof for reducing the blood glucose level, in particular, for the treatment of diabetes.
Absstract of: WO2025202984A1
The present invention concerns h-ferritin complexes loaded with anti-tumoral drugs for the treatment of cancer through Boron Neutron Capture Therapy.
Absstract of: WO2025203087A1
The present disclosure discloses a recombinant construct including a vector and a recombinant nucleic acid molecule (1). The vector including at least one promoter region (13). The recombinant nucleic acid molecule (1) is encoded at least by SEQ ID No. 1. The recombinant nucleic acid molecule (1) is disposed downstream of the at least one promoter region (13) to enable transcription of the recombinant nucleic acid molecule (1) by the promoter region (13) to a plurality of messenger ribonucleic acid (mRNA) molecules encoded by SEQ ID No. 9.
Absstract of: WO2025202360A1
The present invention relates to aqueous RNA compositions that are suitable for storage, comprising Tris, a saccharide, and phosphate anions. The present invention also relates to methods of producing such aqueous RNA compositions, as well as their use in therapy and prevention of infectious diseases.
Absstract of: WO2025200517A1
The present invention provides a lipid material for nucleic acid delivery, wherein the lipid material comprises a compound having structure I. The present invention also provides use of the lipid material for nucleic acid delivery in the preparation of a therapeutic drug for one or more selected from an infectious disease, a tumor disease, a congenital hereditary disease, and an immune disease. By means of the lipid material provided in the present invention and adopting a nucleic acid drug carrier strategy with high efficiency and low toxicity, a novel ionizable lipid and an auxiliary lipid material are mixed to encapsulate nucleic acid drugs, so that efficient and safe delivery of the nucleic acid drugs in vivo is achieved, and the druggability of the nucleic acid drugs is improved.
Absstract of: WO2025207519A1
Embodiments of the present disclosure pertain to an active agent carrier that includes a disc-shaped membrane with a plurality of self-assembled amphiphilic block copolymers encased by membrane stabilizing agents, where the amphiphilic block copolymers include hydrophilic blocks and hydrophobic blocks, and where at least one active agent is associated with the disc-shaped membrane. Tunable numbers of targeting agents may also be associated with the disc-shaped membrane. Additional embodiments pertain to methods of delivering one or more active agents to a subject by administering to the subject an active agent carrier of the present disclosure. Further embodiments pertain to methods of making an active agent carrier of the present disclosure.
Absstract of: EP4624516A1
Provided are a novel lipid derivative compound including oligo-γ-glutamic acid, a lipid nanoparticle composition including the same, and the like. According to the present disclosure, the compound may form lipid nanoparticles by replacing PEGylated lipid, thereby preventing side effects such as anaphylaxis and exhibiting excellent in vivo stability.
Absstract of: EP4623901A1
Provided is an efficient transdermal delivery system based on an acidic group-containing biomaterial produced by bonding or physically compounding a tertiary amine oxide group-containing polymer to an acidic group-containing biomaterial or an acidic group-containing biomaterial nanogel. The efficient transdermal delivery system does not require a subcutaneous injection. After being smeared or coated on a skin, the transdermal delivery system can effectively penetrate through the stratum corneum of the skin and enter the subcutaneous layers to exert prominent medical aesthetic effects such as wrinkle and fold correction, or to achieve the transdermal delivery of heparin for thrombolysis, or to achieve the delivery of a drug.
Absstract of: WO2024112867A1
Nanoparticles having a calcium core, such as calcium hydroxide (Ca(OH)2) and calcium carbonate (CaCO3) particles are provided. The nanoparticles can further include a shell such as one formed of silica or oleic acid. The nanoparticles can further include a coating, such as one formed of polyethylene glycol and optionally further including a lipid. The nanoparticles can further include a targeting agent, such as one that targets dendritic cells, T cells, or other immune cells. The nanoparticles can further include or otherwise be used in combination with an active agent, optionally selected from an antigen, chemotherapeutic drug, immune system modulator, or immune checkpoint modulator. Pharmaceutical compositions including the nanoparticles and methods of use thereof for increasing immune response, e.g., against cancer and infections are also provided.
Absstract of: WO2024110757A1
The invention provides constructs, pharmaceutical compositions, methods of preparing a ferritin nanocage, ferritin nanocages, methods of treating or preventing a disease in a subject, and methods of raising an immune response against an antigen. Exemplary constructs include two ferritin subunits connected by a linker, wherein the linker includes a cleavage site, wherein the linker is arranged to prevent the ferritin subunits from self-assembling into a ferritin nanocage, and wherein cleavage of the linker at the cleavage site does not prevent the ferritin subunits from self-assembling into a ferritin nanocage.
Absstract of: US2025268840A1
There are disclosed methods of treating a subject or an object in need thereof, the method comprising administering compositions comprising nano-elements containing: a) at least one water-insoluble thermoplastic compound (WITC), capable of forming a core; and b) at least one active agent which can be disposed in said core or in shells surrounding the core. The nano-elements, having an average diameter in the sub-micron range, are constituted of materials having a low vapor pressure and are dispersible in a polar carrier. Methods for preparing these nano-elements, and administering them, so as to treat conditions corresponding to the active agents contained therein, are also provided.
Nº publicación: EP4622673A1 01/10/2025
Applicant:
UNIV MUENCHEN LUDWIG MAXIMILIANS [DE]
Ludwig-Maximilians-Universit\u00E4t M\u00FCnchen
Absstract of: WO2024110492A1
The invention relates to a carrier comprising at least one polar cationizable domain (PCD), two or more apolar cationizable domains (ACD) and at least one branching connector (BC), wherein the two or more ACDs are linked by at least one branching connector to at least one PCD, wherein the PCD is an oligo(alkylamino) acid, an ε-poly-L-lysine or an ε-poly-L-lysine-6-Ahx, and the ACD is a lipo amino fatty acid (LAF) comprising a tertiary amine. The invention further relates to nanoparticles comprising said carrier and a cargo, wherein the cargo comprises a nucleic acid and/or a protein and to a pharmaceutical composition comprising said nanoparticles and to its use in therapy or in in vitro culture.
BOPI
Electronic site
